Zydus Cadila - Company & Market Research Reports

Zydus Cadila Pharmaceutical is a global healthcare provider. The origins of this group go back to 1952, however in 1995 this group restructured its operations and the Cadila group were taken over by the Zydus group. It is the only Indian pharma company to launch its own patented NCE. They developed a drug for diabetic dyslipidemia, Lipaglyn. This is the first drug to be approved for this disease. They are the 4th largest in the Indian pharma market. Other than their successful sales from India, Zydus gains a wider market share through its subsidiaries in the U.S, Europe (France and Spain), South Africa and Latin America. From their beginning in 1995 to today Zydus has shown major growth rates in revenue.

Humira Biosimilars Clinical Trial Insight - Product Thumbnail Image

Humira Biosimilars Clinical Trial Insight

  • Clinical Trials
  • 80 Pages
From
From
PDE Inhibitors Market, 2016-2026 - Product Thumbnail Image

PDE Inhibitors Market, 2016-2026

  • Report
  • 223 Pages
From
From
From
From
From
From
From
From
Hepatitis A - Pipeline Insight, 2018 - Product Thumbnail Image

Hepatitis A - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
From
From
From
From
Loading Indicator
adroll